523 results on '"Broijl, A"'
Search Results
2. HOVON 104, long‐term follow‐up of bortezomib‐dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients
3. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
4. Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
5. Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research
6. Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study
7. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
8. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
9. P804: PLASMA CELL LEUKEMIA-LIKE TRANSCRIPTOME OF BONE MARROW PLASMA CELLS AND CIRCULATING TUMOR CELL LEVELS IN PERIPHERAL BLOOD COMPLEMENTARILY DEFINE HIGH-RISK IN NEWLY DIAGNOSED MULTIPLE MYELOMA
10. P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
11. P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
12. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
13. NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
14. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
15. Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
16. P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
17. HOVON 104, long‐term follow‐up of bortezomib‐dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients.
18. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
19. Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
20. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
21. Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research
22. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
23. Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
24. Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis
25. B05 PLASMA CELL LEUKEMIA-LIKE STATUS HAS INDEPENDENT PROGNOSTIC VALUE IN THE CONTEXT OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM
26. P37 MULTIPLE MYELOMA MONITORING FROM ARCHIVED SERUM PROTEIN ELECTROPHORESIS GELS BY MASS SPECTROMETRY AND DE NOVO SEQUENCING
27. B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS
28. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
29. Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial
30. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
31. Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
32. Treatment emergent peripheral neuropathy in the CASSIOPEIA trial
33. Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
34. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
35. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
36. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
37. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
38. P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES
39. P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE
40. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
41. P-008 Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy
42. P-031 Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy
43. P-050 GEN3014 (HexaBody-CD38) versus daratumumab in patients with relapsed/ refractory multiple myeloma: design of randomized head-to-head expansion cohort of phase 1/2 trial
44. Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
45. P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
46. P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
47. P804: PLASMA CELL LEUKEMIA-LIKE TRANSCRIPTOME OF BONE MARROW PLASMA CELLS AND CIRCULATING TUMOR CELL LEVELS IN PERIPHERAL BLOOD COMPLEMENTARILY DEFINE HIGH-RISK IN NEWLY DIAGNOSED MULTIPLE MYELOMA
48. B01: STROMAL CELL-NEUTROPHIL INTERACTIONS PROMOTE A PRO-TUMOR ENVIRONMENT IN MULTIPLE MYELOMA
49. Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network
50. Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.